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Summary
The autonomic nervous system (ANS) conveys neuronal input from the brain to the stomach. We 
investigated mechanisms through which urocortin 1 (UCN1) injected intracerebroventricularly 
(ICV, 300 pmol/rat) inhibits circulating ghrelin in rats. This was achieved by assessing (1) the 
induction of c-fos gene expression as a marker of neuronal activation in specific hypothalamic and 
caudal brainstem regulating ANS; (2) the influence of vagotomy and pharmacological blockade of 
central and peripheral α- and β-adrenergic receptor (AR) on ICV UCN1 -induced reduction of 
plasma ghrelin levels (determined by ELISA); and (3) the relevance of this pathway in the feeding 
response to a fast in rats. UCN1 increased c-fos mRNA expression in key brain sites influencing 
sympathetic activity namely the hypothalamic paraventricular and ventromedial nuclei, locus 
coeruleus, nucleus of the solitary tract, and rostral ventrolateral medulla, by 16-, 29-, 6-, 37-, and 
13-fold, respectively. In contrast, the dorsal motor nucleus of the vagus had little c-fos mRNA 
expression and ICV UCN1 induced a similar reduction in acylated ghrelin in the sham-operated 
(31%) and vagotomized (41%) rats. An intraperitoneal (IP) injection of either a non-selective α- or 
selective α2-AR antagonist reduced, while a selective α2-AR agonist enhanced ICV UCN1-
induced suppression of plasma acylated ghrelin levels. In addition, IP injection of a non-selective 
β- or selective β1-AR agonist blocked, and selective β1-AR antagonist augmented, the ghrelin 
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response to ICV UCN1. The IP injections of a selective α1- or non-selective β or β2-AR 
antagonists, or any of the pretreatments given ICV had no effect. ICV UCN1 reduced the 2-h food 
intake in response to a fast by 80%, and this effect was partially prevented by a selective α2-AR 
antagonist. These data suggest that ICV UCN1 reduces plasma ghrelin mainly through the brain 
sympathetic component of the ANS and peripheral AR specifically α2-AR activation and 
inactivation of β1-AR. The α2-AR pathway contributes to the associated reduction in food intake.
Keywords
Acylated ghrelin; Adrenergic receptors; Food intake; Urocortin 1; Stress; Rikkunshito
1. Introduction
Stress is well established to influence feeding behaviors and metabolism in both humans and 
rodents (Patterson and Abizaid, 2013). Corticotropin-releasing factor (CRF) plays a key role 
in coordinating the hormonal, autonomic, behavioral and visceral components of the acute 
stress response (Stengel et al., 2010a). In rodents, CRF administered into the brain induces 
stress-like behaviors, including increased anxiety-like manifestations and food intake 
suppression (Stengel and Taché, 2014; Zorrilla et al., 2003). Urocortin 1 (UCN1) is a 
member of the mammalian CRF-related peptide that is mainly localized in the Edinger–
Westphal nucleus, and to a lesser extent, in the olfactory bulb, supraoptic nucleus, 
ventromedial hypothalamus (VMH) and lateral hypothalamic area (Kozicz et al., 1998; Shah 
et al., 2013). Evidence suggests that experimental stressors activate UCN1 neurons in the 
Edinger-Westphal nucleus (Gaszner et al., 2004). Both CRF and UCN1 mediate their actions 
through the activation of CRF receptor subtypes 1 and 2 (CRF1 and CRF2, respectively); 
however, CRF and UCN1 exhibit differential binding affinities. UCN1 displays high affinity 
to both CRF receptor subtypes, while CRF is a preferential CRF1 agonist and has a low 
affinity to CRF2 (Vaughan et al., 1995).
It is well documented that UCN1 injected intracerebroventricularly (ICV) is more potent 
than CRF to suppress fasting- or dark phase-induced food intake without inducing 
conditioned taste aversion or visceral illness in rodents (Benoit et al., 2000; Smagin et al., 
1998; Spina et al., 1996). ICV UCN1-induced food intake inhibition action is mediated 
mainly through the activation of brain CRF2 in rats (Smagin et al., 1998; Yakabi et al., 
2011). Several brain sites expressing high density of CRF2 (Bittencourt et al., 1999) and 
regulate the autonomic nervous system (ANS) (Saper, 2002) have been identified to be 
responsive to UCN1, which results in a CRF2-mediated anorexigenic response in rats, 
namely the lateral septum (Bakshi et al., 2007), paraventricular nucleus of the hypothalamus 
(PVN) (Currie et al., 2001), VMH (Chen et al., 2012; Ohata et al., 2000), and dorsal raphe 
(Weitemier and Ryabinin, 2006). In addition, based on the observation that UCN1 injected 
into the fourth brain ventricle is still able to reduce food intake in chronically decerebrated 
rats (Daniels et al., 2004), hindbrain structures are believed to be involved in this response. 
This is consistent with the earlier report that the nucleus tractus solitarius (NTS) is a 
brainstem site that is responsive to UCN1 (Grill et al., 2000).
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Several potential mechanisms could participate in the anorexic effects of ICV UCN1. The 
ICV injection of UCN1 induces a CRF2-mediated inhibition of gastric emptying (Martinez 
et al., 2004; Yakabi et al., 2011) and hyperglycemia (Grill et al., 2000) in rodents. Both 
effects are known to reduce feeding (Cha et al., 2008; Phillips and Powley, 1996). In 
addition, we have recently reported that UCN1 ICV acts through the CRF2 receptor to 
decrease circulating acylated ghrelin (Yakabi et al., 2011), which is the only known 
orexigenic hormone that is produced peripherally by gastric endocrine X/A cells but acts 
centrally (Hosoda et al., 2002; Muller and Tschop, 2013). Of functional relevance, we have 
shown that the exogenous injection of ghrelin or the ghrelin enhancer rikkunshito (Takeda et 
al., 2012) restored food intake in ICV UCN1-injected rats (Yakabi et al., 2011). However, 
the mechanism(s) through which the circulating ghrelin is suppressed by the central 
administration of UCN1 is yet to be elucidated. Changes in the ANS activity influence 
gastric ghrelin secretion (Hosoda and Kangawa, 2008), and various local classical 
neurotransmitters and neuropeptides are reportedly to influence ghrelin release (de la Cour 
et al., 2007; Stengel et al., 2011). Previous reports indicate that centrally injected UCN1 
effects on gastric function involve the ANS (Czimmer et al., 2006; De Fanti and Martinez, 
2002).
In the present study, we first delineated the ANS pathway(s) that contributes to the decreased 
circulating ghrelin induced by ICV injection of UCN1 in rats. This was achieved by surgical 
approach (vagotomy) and mapping the induction of c-fos gene expression as a marker of 
neuronal activation (Krukoff, 1993), in specific hypothalamic (PVN, VMH) and brainstem 
[LC (locus coeruleus), NTS, DMN (dorsal motor nucleus), RVLM (rostral ventrolateral 
medulla)] nuclei that regulate the ANS (Saper, 2002; Toth et al., 1999; Travagli et al., 2006). 
Then, we assessed the related peripheral adrenergic mechanisms using the pharmacological 
blockade of central and peripheral α- and β-adrenergic receptors (ARs). Lastly, we 
examined the functional implications of ghrelin suppression in the inhibition of food intake 
induced by ICV UCN1 using blockade of identified AR pathways alone or in combination 
with a ghrelin receptor antagonist or the ghrelin enhancer, rikkunshito (Takeda et al., 2012).
2. Materials and methods
2.1. Animals
Eight-week-old male Sprague-Dawley rats (weight, 240–280g) were purchased from Japan 
SLC, Inc. (Shizuoka, Japan). All animals were housed in polycarbonate cages in room with 
controlled conditions of ambient temperature (23 ± 3°C), humidity (50 ± 20%), and lighting 
(12-h light:dark cycle starting at 7:00 PM). Animals were maintained with water and 
standard laboratory food ad libitum. Access to the standard laboratory food was removed 16 
h before experiments, which were conducted between 1 and 5 h after the beginning of the 
light cycle to avoid the influences of diurnal rhythms. All experimental procedures were 
performed according to the Guidelines for the Care and Use of Laboratory Animals and 
approved by the Laboratory Animal Committee of Tsumura & Co. (Tokyo, Japan).
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2.2. Surgery
2.2.1. Intracerebroventricular cannula—Rats under sodium pentobarbital (50 mg/kg, 
intraperitoneal, IP) anesthesia were placed on a stereotaxic apparatus (Japan SLC Inc., 
Shizuoka, Japan). A stainless steel guide cannula (AG-8; Eicom, Kyoto, Japan) was 
implanted into the right lateral ventricle using the following coordinates derived from the rat 
brain atlas (Paxinos and Watson, 1998): 0.8 mm posterior and 1.4 mm lateral from the 
bregma and 3.4 mm ventral from the skull surface. Rats were singly housed after the surgery 
and had at least a recovery period of 5 days before the start of the treatment.
2.2.2. Subdiaphragmatic vagotomy—The surgery was performed at least 10 days after 
ICV cannulation as previously described (Hosoda and Kangawa, 2008; Takeda et al., 2008) 
in pentobarbital-anesthetized rats (40 mg/kg, IP). Following a laparotomy, both vagal trunks 
located at the lower esophagus were resected, and a pyloroplasty was performed to widen 
the pylorus and prevent pyloric stenosis. Sham operations consisted of the opening of the 
abdomen and exposure of the internal organs. The abdomen was closed by sutures. Animals 
had at least 6 days of recovery time and maintained under standard ad libitum food.
2.3. Drugs and treatments
Rat UCN1 was purchased from Peptide Institute, Inc. (Osaka, Japan). Phentolamine 
hydrochloride (non-selective α-AR antagonist), prazosin hydrochloride (selective α1-AR 
antagonist), yohimbine hydrochloride (selective α2-AR antagonist), propranolol (non-
selective β-AR antagonist), atenolol (selective β1-AR antagonist), ICI-118,551 (selective β2-
AR antagonist), synephrine (non-selective α-AR agonist), phenylephrine hydrochloride 
(selective α1-AR agonist), clonidine hydrochloride (selective α2-AR agonist), isoproterenol 
hydrochloride (non-selective β-AR agonist), denopamine (selective β1AR agonist), and 
salbutamol (selective β2-AR agonist) were all purchased from Sigma-Aldrich Chemical Co. 
(St. Louis, MO, USA). The growth hormone secretagogue receptor type 1a (GHS-R1a) 
antagonist, [D-Lys3]-GHRP-6, was purchased from Bachem, Inc. (Torrance, CA, USA). 
These compounds were dissolved in saline when injected IP and in phosphate-buffered 
saline (PBS) when injected ICV. Rikkunshito, which is a Japanese kampo medicine, was 
supplied from Tsumura & Co. (Tokyo, Japan) in the form of a powdered extract obtained by 
spray-drying a hot water extract mixture of the following eight crude drugs: Atractylodis 
lanceae rhizoma (4.0 g), Ginseng radix (4.0 g), Pinelliae tuber (4.0 g), Poria (4.0 g), Zizyphi 
fructus (2.0 g), Aurantii nobilis pericarpium (2.0 g), Glycyrrhizae radix (1.0 g), and 
Zingiberis rhizoma (0.5 g). Rikkunshito was dissolved in distilled water for oral 
administration. Components of rikkunshito for binding assay were dissolved in dimethyl 
sulfoxide (DMSO, final dilution: 1%). Other analytical reagents were highest-purity 
commercially available products.
Treatments were performed on lightly hand-restrained rats in the following volumes: 10 
µL/rat for ICV injection, 1 mL/kg for IP or intravenous (IV) injection through tail vein, and 
10 mL/kg for orogastric administration. Rats were handled daily more than 5 days prior to 
treatment to minimize stress during the procedure.
Yakabi et al. Page 4
Psychoneuroendocrinology. Author manuscript; available in PMC 2018 May 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.4. Ghrelin determination
Rats were euthanized by decapitation, and trunk blood (approximately 4 mL) was collected 
in cold polypropylene tubes containing 8.0 mg ethylenediaminetetraacetic acid and 0.8 mg 
aprotinin. Samples were centrifuged at 10,000 × g at 4°C for 3 min. The supernatant was 
acidified with 1M HCl (1/10 volume) and stored at −80°C until the ghrelin assays were 
performed. Plasma ghrelin levels were determined using active ghrelin and des-acyl ghrelin 
Enzyme-Linked Immunoassay Kits (Mitsubishi Chemical Corp., Tokyo, Japan). The 
detection limits for the acylated and des-acyl ghrelin were 2.7 fmol/mL and 12.3 fmol/mL, 
respectively. The intraassay coefficients of variation for the acylated and des-acyl ghrelin 
were 0.8–4.8% and 2.2–5.5%, respectively, and the interassay coefficients of variation for 
the acylated ghrelin and des-acyl ghrelin were 2.8–6.4% and 1.9–9.0%, respectively.
2.5. Binding affinity of rikkunshito for ARs
For the α2A-AR binding assay, insect Sf9 cells expressing human recombinant α2A-AR 
were homogenized in modified Tris–HCl buffer and aliquots were incubated with 1 nM [3H] 
MK-912 for 60 min at 25 °C. Nonspecific binding was estimated in the presence of 10 µM 
WB-4101 (Uhlen et al., 1994). For α2B-AR, CHO-K1 cells stably transfected with a plasmid 
encoding human α2B-AR were homogenized in modified Tris–HCl buffer using standard 
techniques and aliquots were incubated with 2.5 nM [3H] rauwolscine for 60 min at 25°C. 
Nonspecific binding was estimated in the presence of 10 µM prazosin (Uhlen et al., 1998). 
For α2C-AR, insect Sf9 cells expressing human recombinant α2C-AR were homogenized in 
modified Tris–HCl buffer and aliquot was incubated with 1 nM [3H] MK-912 for 60 min at 
25 °C. Nonspecific binding was estimated in the presence of 10 µM WB-4101 (Uhlen et al., 
1994). Radio binding assays for α1 and β-AR are detailed in Supplementary Material 1. The 
half-maximal inhibitory concentration (IC50) values were determined by nonlinear, least-
squares regression analysis using the MathIQ™ statistical software (ID Business Solutions 
Ltd., Surrey, UK).
Supplementary Material 1 related to this article can be found, in the online version, at http://
dx.doi.org/10.1016/j.psyneuen.2014.09.003.
2.6. Experimental protocols
All experiments were performed in 16 h-fasted rats with no access to food post ICV 
injection except otherwise mentioned.
2.6.1. c-Fos gene expression in rat brain induced by ICV UCN—Rats with chronic 
ICV cannula were injected ICV either with PBS or UCN1 (300 pmol/rat) and were 
anesthetized 1 h later with sodium pentobarbital (50 mg/kg, IP). The brain was collected and 
processed for c-fos mRNA detected by in situ hybridization as detailed previously (Yakabi et 
al., 2011) (Supplementary Material 2). c-Fos mRNA-positive cells in the PVN, VMH, LC, 
NTS, DMN and RVLM were unilaterally counted.
Supplementary Material 2 related to this article can be found, in the online version, at http://
dx.doi.org/10.1016/j.psyneuen.2014.09.003.
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2.6.2. Effects of ICV UCN1 on acylated and des-acyl ghrelin plasma levels in 
sham or vagotomized rats—Chronically ICV cannulated rats with sham or 
subdiaphragmatic vagotomy performed 6 days earlier were divided into two groups (n = 8–
10/group) and injected ICV with either PBS or UCN1 (300 pmol/rat). Rats were euthanized 
by decapitation 2 h after ICV injection. The trunk blood was collected for the determination 
of acylated and des-acyl ghrelin levels in plasma. The ICV dose of UCN1 was selected, 
based on our previous dose-response studies showing the maximal suppression of 24-h food 
intake in rats and reduced fasting ghrelin levels at 1-h and 2-h post-ICV injection compared 
to ICV PBS (Yakabi et al., 2011).
2.6.3. Effects of AR antagonists, agonists or rikkunshito on ICV UCN 1-
induced reduction of plasma acylated ghrelin levels—Chronically ICV-cannulated 
rats were divided into five groups (n = 8–17/group) and injected ICV with PBS or UCN1 
(300 pmol/rat) after the following treatments given either IP 15 min before or ICV 
simultaneously: saline, non-selective α-AR antagonist (phentolamine, 5 mg/kg, IP or 0.05 
mg/rat, ICV), selective α1-AR antagonist (prazosin, 5 mg/kg, IP or 0.50 mg/rat, ICV), 
selective α2-AR antagonist (yohimbine, 5 mg/kg, IP or 0.04 mg/rat, ICV). The regimen of 
AR blockade was based on previous reports (Becker et al., 1999; Hosoda and Kangawa, 
2008). In other sets of experiments, the IP pretreatment were given either 15 min before or 
simultaneously ICV UCN1 with the following β-AR antagonists: non-selective (propranolol, 
3 mg/kg), β1-selective (atenolol, 10 mg/kg), or β2-selective (ICI-118,551, 0.1 mg/kg) 
(Hosoda and Kangawa, 2008; Zhao et al., 2010); the following β-AR agonists: non-selective 
(isoproterenol, 0.1 mg/kg), β1-selective (denopamine, 0.1 mg/kg) or β2-selective 
(salbutamol, 0.1 mg/kg); or the following α-AR agonists: non-selective (synephrine, 5 mg/
kg), α1-selective (phenylephrine, 5 mg/kg), or α2-selective (clonidine, 5 mg/kg) (Hosoda 
and Kangawa, 2008). In the last set of study, the following pretreatments were given 1 h 
before ICV UCN1: orogastric gavage with distilled water (10 mL/kg) or rikkunshito (0.5 
g/kg or 1.0 g/kg). This regimen of administration was based on our previous studies (Takeda 
et al., 2008; Yakabi et al., 2011). In all experiments, the trunk blood was collected 2 h after 
the ICV injection to determine the acylated ghrelin levels.
2.6.4. Effects of a selective α2-AR antagonist on ICV UCN 1-induced reduction 
of food intake—Chronically ICV-cannulated rats were pretreated IP with a selective α2-
AR antagonist (yohimbine, 5 mg/kg) or vehicle and 15min later injected ICV with UCN1 
(300 pmol/rat). To assess the effects of the ghrelin antagonist on the selective α2-AR 
antagonist activities, rats were first injected IP with saline or the selective α2-AR antagonist, 
and 15 min later, rats received an IV injection of either saline or [D-Lys3]-GHRP-6 (3.7 
mg/kg) followed 1 min later by ICV PBS or UCN1 (300 pmol/rat). Preweighed chow was 
placed in each cage, and the 2-h cumulative food intake was monitored immediately after 
ICV injection.
2.7. Statistical analysis
All values are presented as the mean ± standard error of the mean. Statistical analyses of the 
mean values of two groups were performed using Student’s t-test or the Aspin-Welch t-test. 
The mean values of multiple groups were determined by two-way factorial analysis of 
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variance (ANOVA) followed by the Bonferroni post hoc test or one-way analysis of variance 
(ANOVA) followed by Dunnett’s test or Steel’s test. For all tests, probability (P) values of 
<0.05 were considered statistically significant.
3. Results
3.1. ICV UCN1 injection induces c-fos mRNA expression in specific brain nuclei
ICV UCN1 (300 pmol/rat) did not influence c-fos mRNA expression in the DMN while 
increasing the number of labeled cells in the PVN, VMH, LC, NTS and RVLM by 16-, 29-, 
6-, 37- and 13-fold, respectively, compared with ICV vehicle-injected rats as monitored 1 h 
after the peptide injection by in situ hybridization (Supplementary Fig. S1 and Table S1).
Supplementary Table S1 and Fig. S1 related to this article can be found, in the online 
version, at http://dx.doi.org/10.1016/j.psyneuen.2014.09.003.
3.2. Vagotomy did not influence ICV UCN1-induced reduction of plasma acylated and des-
acyl ghrelin levels
In the sham-operated, fasted rats, UCN1 (300 pmol/rat, ICV) reduced the plasma levels of 
acylated and des-acyl ghrelin by 31% and 25%, respectively, compared to ICV vehicle 
injection as monitored at 2 h after the injection (Fig. 1A and B). Similarly, in the rats with 
subdiaphragmatic vagotomy, ICV UCN1 significantly decreased plasma acylated and des-
acyl ghrelin levels by 41% (P < 0.05) and 33% (P < 0.05), respectively (Fig. 1A and B, n = 
8–10). The magnitude of the reduction did not significantly differ between the sham and 
vagotomized groups. It is to note that the vagotomized rats injected ICV with vehicle 
showed a trend to have an increase in acylated ghrelin (21%) and des-acyl ghrelin (22%), 
which did not reach significance by using the two-way factorial analysis of variance 
(ANOVA) followed by the Bonferroni post hoc test (Fig. 1A and 1B). As acylated ghrelin is 
the active form of the peptide that activates GHS-R1a to stimulate food intake (Stengel et al., 
2010b), in all subsequent experiments, we limited the plasma determination to the acylated 
form of ghrelin.
3.3. Effects of IP injection or ICV injection of AR antagonists, agonists or rikkunshito on 
ICV UCN1-induced decreases in plasma acylated ghrelin
In IP vehicle-pretreated, fasted rats, ICV UCN1 (300 pmol/rat, n = 38) induced a significant, 
50–59% reduction of fasted plasma levels of acylated ghrelin compared with ICV vehicle 
(Fig. 2A–D, P < 0.001, P < 0.01, P < 0.01 and P < 0.05, respectively [n = 8–14]). IP 
pretreatment with the non-selective α-AR antagonist (phentolamine) or selective α2-AR 
antagonist (yohimbine) before ICV UCN1 increased significantly and similarly plasma 
levels of acylated ghrelin compared with those of the vehicle pretreated-plus-ICV UCN1 
group (58.5 ± 2.5 fmol/mL, 58.6 ± 4.5 fmol/mL vs. 43.5 ± 4.5 fmol/mL respectively, P < 
0.05), while the selective α1-AR antagonist (prazosin) had no effect (44.9 ± 3.6 fmol/mL; 
Fig. 2A). However, in the phentolamine- or yohimbine-pretreated rats, the values remained 
significantly lower than those of the control group (IP saline + ICV PBS: 85.5 ± 6.7 
fmol/mL, Dunnett’s test: P < 0.05; Fig. 2A, n = 14–17/group). Conversely, the IP injection 
of the selective α2-AR agonist (clonidine, P < 0.01), unlike a non-selective α-AR agonist 
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(synephrine) or a selective α1-AR agonist (phenylephrine), further decreased the plasma 
acylated ghrelin levels induced by ICV UCN1 (Fig. 2B, n = 8/group and Supplementary Fig. 
S2, n = 8/group). In a preliminarily study, the selective α2-AR antagonist did not influence 
the acylated ghrelin levels in fasted rats. Furthermore, a previous report has shown no 
significant changes in the fasting levels of ghrelin induced by the non-selective α-AR 
antagonist phentolamine (Hosoda and Kangawa, 2008).
Supplementary Fig. S2 related to this article can be found, in the online version, at http://
dx.doi.org/10.1016/j.psyneuen.2014.09.003.
With regard to the influences of β-ARs, we found that the selective β1-AR antagonist 
(atenolol, P < 0.05), but not the non-selective β-AR antagonist (propranolol) or the selective 
β2-AR antagonist (ICI-118,551), further decreased the plasma acylated ghrelin levels 
induced by ICV UCN1 (Fig. 2C, n = 8/group). Conversely, the non-selective β-AR agonist 
(isoproterenol, P < 0.01) or the selective β1-AR agonist (denopamine, P < 0.01), but not the 
selective β2-AR agonist (salbutamol), prevented the decreased plasma acylated ghrelin levels 
elicited by ICV UCN1, leading to acylated ghrelin values not significantly different from 
those of ICV saline-treated rats (Fig. 2D, n = 8/group).
When injected ICV, the non-selective α-AR antagonist (phentolamine), the selective α1-AR 
antagonist (prazosin) and the selective α2-AR antagonist (yohimbine) did not influence the 
reduction of plasma acylated ghrelin levels induced by ICV UCN1 (Fig. 3A, n = 8/group). 
Lastly, the oral administration of rikkunshito significantly inhibited (P < 0.05) the decreased 
plasma acylated ghrelin levels when given at 1 g/kg, while at a dose of 0.5 g/kg, it had no 
effect (Fig. 3B, n = 14–16/group).
3.4. Effects of selective α2-antagonist (yohimbine) in combination with [D-Lys3]-GHRP-6 on 
decreased food intake induced by ICV UCN1
In the control-pretreated rats, ICV UCN1 induced a significant 87% reduction of the 
cumulative 2-h food intake response to overnight fasting (control: IP saline, IV saline, ICV 
PBS: 4.9 ± 0.4 g/2 h; IP saline, IV saline, ICV UCN1: 0.7 ± 0.3 g/2 h, P < 0.001; Fig. 4, n = 
7–8/group). IP pre-treatment with the selective α2-AR antagonist (yohimbine) prevented 
ICV UCN1 inhibitory effects (IP yohimbine, IV saline, ICV UCN1: 3.6 ± 1.0 g/2h, P < 
0.05) while not influencing significantly the feeding response to the fast (IP yohimbine, IV 
saline, ICV PBS: 6.8 ± 1.0 g/2h vs. IP saline, IV saline, ICV PBS: 6.4 ± 0.7 g/2h). [D-Lys3]-
GHRP-6 injected IV did not influence the 2-h cumulative food intake in vehicle-treated 
control rats while completely blocking the normalization of feeding induced by IP 
yohimbine in ICV UCN1-treated rats (Fig. 4, n = 7–8/group).
3.5. In vitro binding assays of rikkunshito components on ARs
The AR binding-inhibitory activities (IC50) of the crude drug components contained in 
rikkunshito were tested in transfected cells with human AR subtypes. As shown in Table 1, 
glycycoumarin 6-, 8-shogaol and 10-gingerol, and eudesmol display inhibitory activity to 
α2A-AR and differential activities on α1-AR or β1,3-AR (Supplementary Table S2).
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Supplementary Table S2 related to this article can be found, in the online version, at http://
dx.doi.org/10.1016/j.psyneuen.2014.09.003.
4. Discussion
We found that ICV UCN1 -induced reduction of plasma ghrelin levels was not altered by 
vagotomy and attenuated by the peripheral blockade of α2-AR and restored by the activation 
of β1-AR in rats. Conversely, α2-AR agonist and β1AR antagonist enhanced the inhibitory 
effect of ICV UCN1. This α2-AR-ghrelin inhibitory pathway has functional relevance since 
yohimbine prevented the anorexic effect of ICV UCN1 and the α2-AR action was abolished 
by the ghrelin receptor antagonist.
UCN1 injected ICV at 300 pmol/rat reproducibly decreased by 50–59% plasma levels of 
acylated ghrelin in fasted rats consistent with our previous report (Saegusa et al., 2011; 
Yakabi et al., 2011). UCN1 action is brain-mediated and does not reflect peptide leakage 
into the periphery since systemic injection of UCN1 increases the total ghrelin plasma levels 
in fed rats or had no effect in fasted state (Wang et al., 2006, 2013). It has been well 
established that the majority of circulating ghrelin is produced by X/A-like cells located in 
the gastric mucosa, as indicated by the pronounced reduction of circulating ghrelin after 
gastrectomy (Ariyasu et al., 2001; Mizutani et al., 2009). The stomach receive prominent 
vagal inner-vation through efferent projections from DMN neurons (Berthoud et al., 1991). 
Central vagal activation (Stengel et al., 2010a) and peripheral acetylcholine administration 
(Shrestha et al., 2009) reportedly increase ghrelin release, while muscarinic receptor 
antagonists suppress ghrelin secretion in fasted rats (Hosoda and Kangawa, 2008). However, 
ICV UCN1 action is unlikely to be mediated by alterations of vagal pathway as reported for 
the inhibitory influence of intracisternally injected UCN1 on gastric emptying in rats 
(Czimmer et al., 2006). This is supported by the observation that subdiaphragmatic 
vagotomy did not alter the magnitude of ghrelin decrease induced by ICV UCN1. Moreover 
c-fos mRNA, which is used as a marker of autonomic neuronal activation (Krukoff, 1993), 
was not induced in DMN neurons by ICV UCN1 (Supplementary Fig. S1 and Table S1) as 
previously observed (Yakabi et al., 2011).
In contrast, there are compelling reports documenting that ICV injection of UCN1 activates 
the core group of autonomic brain structures regulating sympathetic outflow, namely the 
PVN, LC, NTS and RVLM, as monitored by the robust induction of Fos immunoreactivity 
(Bittencourt et al., 1999; Daniels et al., 2004) or c-fos gene expression including under 
similar conditions associated with decreased ghrelin plasma levels (Yakabi et al., 2011) and 
as well as in the present study (Supplementary Fig. S1 and Table S1). We have previously 
reported that ICV UCN1-induced decreased circulating levels of acylated ghrelin are 
mediated by brain CRF2 (Yakabi et al., 2011). Other function data support that activation of 
CRF2 in the PVN stimulates sympathetic nerve activity in rat the viscera (Li et al., 2010). 
These data provide neuroanatomical and functional support for a supra spinal sites of action 
of ICV UCN1 to activate sympathetic outflow. However, it cannot be ruled out that an 
additional thoracic site regulating sympathetic nerve (Quinson et al., 2001) can also be 
involved in ICV UCN1 action.
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Activation of sympathetic pathways release nore-pinephrine from nerve endings that bind to 
ARs, which are classified into α- and β-ARs based on their responses to various 
catecholamines. Previous studies in rats have indicated that fasting plasma levels of ghrelin 
are stimulated by α-AR antagonists and β-AR agonists and inhibited by α-AR agonists 
(Hosoda and Kangawa, 2008). In the present study, a pharmacologic approach using 
peripheral administered selective α- and β-AR subtype antagonists and agonists revealed 
that α2-AR antagonist and β1AR agonist raise, while α2-AR agonist and β1-AR antagonist 
further suppress, the lowered ghrelin plasma levels under conditions of ICV UCN1 injection 
in fasted rats. In support of this assertion, the peripheral injection of the α-AR antagonist, 
phentolamine, and the selective α2-AR antagonist, yohimbine, partially prevented ICV 
UCN1-induced reduction of plasma acylated ghrelin. Conversely, the activation of α2-AR 
with IP injection of clonidine exerted inhibitory effects, as shown by the dose-related further 
decreased of ghrelin plasma levels in ICV UCN1-treated rats (Supplementary Fig. S2). 
Although peripherally administered the selective α2-AR antagonist yohimbine crosses the 
blood-brain barrier (Szemeredi et al., 1991), however it is likely that yohimbine exerts its 
action peripherally, because, when administered ICV, this α2-AR antagonist did not 
influence the decreased ghrelin levels in response to ICV UCN1.
Additional pharmacological studies established the specificity toward peripheral α2-ARs 
since under the same conditions, the α1-AR antagonist (prazosin) or β-AR antagonists 
(propanolol or the β2-AR antagonist, ICI-118,551) had either no effect or further (the β1 -
AR antagonist, atenolol) enhanced the inhibitory effects of ICV UCN1. Likewise, the 
activation of other α- or β-AR subtypes by agonists could not mimic the inhibitory effects of 
UCN1, as shown by the lack of effect of IP injection of α-AR agonist, synephrine, the α1-
AR agonist, phenylephrine, or the β2-AR agonist, salbutamol. In addition, we showed that 
the IP injection of non-selective β-AR agonist, isoproterenol or the selective β1-AR agonist, 
denopamine, restored the basal plasma levels of acylated ghrelin in ICV UCN1-injected rats. 
This may represent a direct action on X/A like cells. This finding is supported by a recent 
study using a culture ghrelinoma cells line showing that ghrelin release is also stimulated 
selectively by the activation of β1-AR agonist and inhibited by β1-AR antagonist, atenonol 
(Zhao et al., 2010). Other in vivo studies have shown that noradrenalin raises the ghrelin 
levels measured in effluent of microdialysis probe implanted into the rat gastric submucosa 
(de la Cour et al., 2007). Additionally, electrically stimulated postganglionic sympathetic 
axons projecting from the celiac ganglions of rats increases ghrelin release (Mundinger et 
al., 2006). Taken together, it may be speculated that the α2-AR antagonist, yohimbine-
induced partial reversal of decreased levels of ghrelin under conditions of sympathetic 
activation by ICV UCN1 may reflect the balance between the inhibitory and stimulatory 
action of peripheral α2-AR and β1-AR activation, respectively. However, the cellular 
mechanisms by which the peripheral α2-ARs contribute to reduce the decline of ghrelin 
plasma levels in ICV UCN1 -treated rats will require further investigation. The α2-AR genes 
were expressed in the rat stomach under our conditions (Supplementary Fig. S3) were 
consistent with a previous study showing α2A-AR, α2B-AR and α2c-AR mRNA levels in the 
gastric mucosa of rats with a more abundant expression of the message for α2A-AR (Gyires 
et al., 2007). This suggests that α2-ARs may directly or indirectly regulate gastric ghrelin 
secretion.
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Supplementary Fig. S3 related to this article can be found, in the online version, at http://
dx.doi.org/10.1016/j.psyneuen.2014.09.003.
Irrespective of the mechanisms involved, we showed that the α2-AR signaling pathway has 
functional relevance to ghlerin secretion. ICV UCN1 decreased the feeding response to an 
overnight fast consistent with previous reports (Benoit et al., 2000; Smagin et al., 1998; 
Spina et al., 1996; Yakabi et al., 2011). This was prevented by the α2-AR antagonist, 
yohimbine. In addition, the simultaneous administration of a ghrelin receptor antagonist and 
α2-AR antagonist completely abolished the effects achieved by α2-AR antagonist 
administration alone. Likewise, rikkunshito established as an enhancer of endogenous 
ghrelin secretion (Takeda et al., 2012) administered orogastrically also increased plasma 
acylated ghrelin inhibited by ICV UCN1. This was associated with the suppression of the 
reductions in food intake (Supplementary Fig. S4) was consistent with our previous data 
(Yakabi et al., 2011). We reported recently that the decreased food intake following ICV 
UCN1 injection was improved by the administration of exogenous acylated ghrelin (Yakabi 
et al., 2011). Collectively, these findings point to a role of ghrelin receptor activation to 
restore feeding behavior under conditions of decreased circulating ghrelin induced by ICV 
UCN1.
Supplementary Fig. S4 related to this article can be found, in the online version, at http://
dx.doi.org/10.1016/j.psyneuen.2014.09.003.
Lastly, in order to validate further our hypothesis that the UCN1-induced reduction in food 
intake involved the activation of peripheral α2-ARs, we assessed whether rikkunshito 
functions as a α2-AR antagonist. Rikkunshito is a mixture of herbal ingredients; therefore, 
in this study, we examined its 34 components using an in vitro AR binding assay. We found 
that several components, namely glycycoumarin, 6- and 8-shogaol, 10-gingerol and 
eudesmol, functioned as α2-AR antagonists. These results suggest that the effects of 
rikkunshito on decreased food intake in response to ICV UCN1 administration may be 
induced through the α2-AR antagonist property of some of its specific components.
In conclusion, the present findings indicate that ICV UCN1 -induced reduction of fasting 
plasma levels of acylated ghrelin is independent from the vagus nerve, while it is associated 
with the activation of specific brain nuclei influencing sympathetic pathways. The peripheral 
AR effectors mediating ghrelin decline after ICV UCN1 involve the activation of α2-ARs 
and the dampening of β1-AR stimulatory effect on ghrelin release. The α2-ARs activation 
and related ghrelin decline contribute to the inhibition of feeding response to a fast induced 
by ICV UCN1. It suggests that α2-AR antagonists may improve alterations of food intake 
linked with suppression of ghrelin under conditions of brain CRF receptor activation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Effects of vagotomy on ICV UCN1-induced decrease in plasma levels of (A) acylated and 
(B) des-acyl ghrelin in rats. Sub-diaphragmatic vagotomy with pyloroplasty or sham 
operation was performed 6 days before the experiments. Rats were euthanized 2 h after ICV 
vehicle (PBS) or UCN1 (300 pmol/rat) administration, and blood samples were collected. 
All values are presented as the mean ± standard error of the mean (SEM) (n = 8–10/group). 
Significance was identified using the Bonferroni post hoc test following two-way analysis of 
variance (ANOVA). *P < 0.05 vs. vagotomy + PBS-treated group.
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Figure 2. 
Effects of IP pretreatment with (A) α-AR antagonists (n = 14–17/group), (B) α-AR agonists 
(n = 8/group), (C) β-AR antagonists (n = 8/group), and (D) β-AR agonists (n = 8/group) on 
plasma acylated ghrelin levels inhibited by ICV UCN1 in rats. IP injection was performed 
15 min before ICV UCN1 (300 pmol/rat) or vehicle, and trunk blood samples were collected 
2 h later. All values are presented as the mean ± SEM. Significance was determined using 
Student’s t-test or one-way ANOVA followed by post hoc Dunnett’s test: *P < 0.05 and **P 
< 0.01 vs. UCN1/saline-treated group.
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Figure 3. 
Effects of ICV with (A) selective α-AR antagonists (n = 8/group) and (B) orogastric 
administration of rikkunshito (n = 14–16/group) on acylated ghrelin levels inhibited by ICV 
UCN1 in rats. ICV was performed simultaneously with UCN1 (300 pmol/rat) or vehicle. 
Distilled water or rikkunshito was orogastrically administered (10 mL/kg) 1 h before ICV 
injection of PBS or UCN1 (300 pmol/rat), the rats were euthanized 2 h later, and blood 
samples were collected. All values are presented as the mean ± SEM. Significance was 
determined using Student’s t-test or ANOVA followed by post hoc Dunnett’s tests: *P < 
0.05 vs. UCN1 + Distilled water-treated group.
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Figure 4. 
Effects of selective α2-AR antagonist (yohimbine) alone or in combination with a ghrelin 
receptor antagonist on food intake in ICV UCN1-treated rats. Saline or yohimbine (5 mg/kg) 
was administrated intraperitoneally 15 min before ICV injection of PBS or UCN1 (300 
pmol/rat). Saline or [D-Lys3]-GHRP-6 (3.7 mg/kg) was administrated intravenously into the 
tail vein 1 min after ICV administration of PBS or UCN1 (300 pmol/rat). Each bar 
represents the mean ± SEM (n = 7–8/group). Significance was determined using Steel’s post 
hoc test following one-way ANOVA analysis *P < 0.05 compared with the UCN1 /saline 
group. Significance was determined using Aspin-welch t-test. +P < 0.05 vs. the UCN1/
selective α2-AR antagonist (yohimbine) group. Significance between PBS and UCN1/saline 
was determined using Student’s t-test.
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